ALDX · CIK 0001341235 · operating
# Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases. The company's pipeline centers on reactive aldehyde species (RASP) modulation, a mechanism targeting aldehyde-related pathways implicated in various inflammatory and metabolic conditions. Its lead candidate, reproxalap, is in Phase III clinical development for dry eye disease and allergic conjunctivitis. The company is also advancing ADX-629, an oral RASP modulator in Phase II trials for COVID-19, atopic asthma, psoriasis, and alcohol intoxication, alongside ADX-2191, a dihydrofolate reductase inhibitor for retinitis pigmentosa. Additional preclinical RASP platform candidates include ADX-248, ADX-743, ADX-631, and ADX-246.
As a clinical-stage biotechnology company, Aldeyra operates primarily on development and research activities with limited commercial revenue. The company maintains a lean operating structure with eight full-time employees and is based in Lexington, Massachusetts. The organization is incorporated in Delaware and trades on the Nasdaq exchange, reflecting its public biotech status.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.56 | $-0.56 | +40.4% | |
| 2024 | $-0.94 | $-0.94 | -46.9% | |
| 2023 | $-0.64 | $-0.64 | +39.6% | |
| 2022 | $-1.06 | $-1.06 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | $-1.40 | $-1.40 | +54.7% | |
| 2014 | $-3.09 | $-2.51 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-27 | 0001193125-26-083012 | SEC ↗ |
| 2024-12-31 | 2025-02-28 | 0000950170-25-030102 | SEC ↗ |
| 2023-12-31 | 2024-03-07 | 0000950170-24-027933 | SEC ↗ |
| 2022-12-31 | 2023-03-09 | 0000950170-23-006998 | SEC ↗ |
| 2021-12-31 | 2022-03-17 | 0000950170-22-004111 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001564590-21-012501 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001564590-20-010493 | SEC ↗ |
| 2018-12-31 | 2019-03-08 | 0001564590-19-006997 | SEC ↗ |
| 2017-12-31 | 2018-03-29 | 0001193125-18-102077 | SEC ↗ |
| 2016-12-31 | 2017-03-30 | 0001193125-17-104228 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001193125-16-523952 | SEC ↗ |
| 2014-12-31 | 2015-03-23 | 0001193125-15-101703 | SEC ↗ |